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Bismuth drugs, despite being clinically used for decades, surprisingly remain in use and eﬀective for the
treatment of Helicobacter pylori infection, even for resistant strains when co-administrated with
antibiotics. However, the molecular mechanisms underlying the clinically sustained susceptibility of H.
pylori to bismuth drugs remain elusive. Herein, we report that integration of in-house metalloproteomics
and quantitative proteomics allows comprehensive uncovering of the bismuth-associated proteomes,
including 63 bismuth-binding and 119 bismuth-regulated proteins from Helicobacter pylori, with over
60% being annotated with catalytic functions. Through bioinformatics analysis in combination with
bioassays, we demonstrated that bismuth drugs disrupted multiple essential pathways in the pathogen,
including ROS defence and pH buﬀering, by binding and functional perturbation of a number of key
enzymes. Moreover, we discovered that HpDnaK may serve as a new target of bismuth drugs to inhibit
bacterium-host cell adhesion. The integrative approach we report, herein, provides a novel strategy to
unveil the molecular mechanisms of antimicrobial metals against pathogens in general. This study sheds
light on the design of new types of antimicrobial agents with multiple targets to tackle the current crisis
of antimicrobial resistance.Introduction
The rapid emergence of drug-resistant pathogens and the deple-
tion of antibiotic pipelines pose great threats to public health.1,2
Alternative strategies are, therefore, urgently needed. Metal ions
historically have been used as antimicrobial agents and disin-
fectants, in particular, certain metals such as Ag+ and Bi3+ exhibit
great potential in killing multidrug-resistant bacteria3 and in
improving the cure rates of infections from resistant strains,4
either when used alone or as antibiotic adjuvants. However, their
modes of action are largely unexplored.5,6Hong Kong, Pokfulam Road, Hong Kong,
y, Guangzhou, P. R. China
of Hong Kong, Hong Kong, P. R. China
l Techniques, Institute of High Energy
g, P. R. China
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is work.Helicobacter pylori is a transmissible human pathogen that is
strongly related to gastrointestinal diseases, even stomach
cancer.7 Owing to the prevalence of antimicrobial resistance,
bismuth-containing quadruple therapy has been suggested as
the rst-line therapy and has shown excellent success rates in
the eradication of H. pylori and even towards established anti-
biotic resistant strains.4,8,9 Despite being used for more than 30
years in the treatment of H. pylori infections, bismuth-based
therapies still possess eﬃcacy towards the pathogen.10 Prior
extensive studies show that proteins appear to be the targets of
bismuth drugs.11,12 However, the systemic response of the
pathogen to bismuth drugs has not yet been explored compre-
hensively, and elucidation of the secret of the sustained
susceptibility of H. pylori to a bismuth drug could shed light on
coping with antimicrobial resistance.
Although proteomics has been well adapted to track proteins
regulated by metallodrugs,13 the systemic identication of metal
or metallodrug binding proteins is particularly important towards
understanding their roles in biology and medicine given that
metals or metallodrugs oen bind and functionally perturb the
biological functions of metalloproteins and/or metal-
loenzymes.11,14 Diﬀerent from proteomics, metalloproteomics
focuses on the large-scale study of metals and their binding
proteins, and is emerging as an invaluable tool to investigate the
role ofmetals in cell biology and disease processes15,16 as well as inThis journal is © The Royal Society of Chemistry 2017
Fig. 2 Identiﬁcation and validation of the Bi-associated proteins in H.
pylori. (A) Molecular structure of Bi3+-TRACER. The nitrilotriacetate
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View Article Onlinethe elucidation of the molecular mechanisms of metallodrugs.17
However, it is a considerable challenge to track proteins that bind
to metallodrugs, particularly in live cells, as the interaction of
metals/metallodrugs with proteins in vivo can be weak or even
transient. This makes them diﬃcult to be identied.
Herein, we integrated in-house metalloproteomics, including
a newly developed uorescent probe-based approach (Bi3+-
TRACER), and continuous-ow gel electrophoresis coupled with
an ICP-MS (GE-ICP-MS)-based approach with quantitative pro-
teomics (Fig. 1) to comprehensively identify bismuth-binding and
bismuth-regulated proteins fromH. pylori and identied a total of
63 Bi-binding and 119 Bi-regulated proteins in the pathogen.
Subsequent bioinformatics analysis and bioassays revealed that
bismuth disrupts multiple essential pathways in H. pylori, e.g. pH
buﬀering and ROS defence. We identify and provide herein the
rst insight that HpDnaK may serve as one of the targets of the
bismuth drug to prevent host-pathogen cell adhesion. The unique
multiple actions of the bismuth drug against H. pylori are there-
fore responsible for its sustained eﬀectiveness. The integrative
approach oﬀers a novel strategy to unveil the modes of action of
metallodrugs in general.(NTA) group was designed to chelate metal ions in a tetradentate
manner. Upon UV activation, the arylazide moiety covalently binds to
Bi-binding proteins. (B) Time-dependent ﬂuorescence spectra of Bi3+-
TRACER (1 mM) and normalized ﬂuorescent intensity at lem ¼ 448 nm
(inset) after the addition of HpHspA (10 mM). It is noted that the binding
of Bi3+-TRACER to HpHspA led to a ca. 5-fold ﬂuorescence
enhancement within 4 min. (C) Fluorescent labelling of His- and Cys-
rich proteins by Bi3+-TRACER on a SDS-PAGE gel. (D) Confocal
imaging of H. pylori cells labelled with Bi3+-TRACER. Bacterial cells
were stained with blue ﬂuorescence after incubation with Bi3+-
TRACER (10 mM), indicating that the probe was diﬀused into H. pylori
cells and labelled the intracellular protein targets. (E) Western blot
analysis of diﬀerentially expressed proteins in CBS-treated H. pylori.
Comparison of the altered protein expression ratios indicated
a general agreement between the western blot and iTRAQ-based MS
analyses. (F–M) Protein thermal melting curves of diﬀerent Bi-target-Results
Systemic identication of bismuth-binding and bismuth-
regulated proteins in H. pylori
To track bismuth-binding proteins in live H. pylori, we devel-
oped a bismuth uorescent probe as a reporter, namely Bi3+-
TRACER (Fig. 2A), by reacting equimolar amounts of Bi3+ (as
bismuth nitrate) with a uorescent ligand NTA-AC18 in a buﬀ-
ered aqueous solution, where the formation of Bi3+-TRACER
was conrmed by ESI-MS (Fig. S1†). The feasibility of Bi3+-
TRACER in labelling proteins in vitro was demonstrated by
recombinant SlyD and HspA from H. pylori, which bind to Bi3+Fig. 1 Identiﬁcation of metal-associated proteomes by integration of
metalloproteomics with quantitative proteomics using Bi3+ as an
example. (A) Bi3+-TRACER-based approach for tracking Bi-binding
proteomes in live cells, including those weakly or transiently bound. (B)
GE-ICP-MS for identiﬁcation of Bi-binding proteins with high aﬃnity.
(C) iTRAQ-based quantitative proteomics for proﬁling bismuth-regu-
lated proteins.
ing proteins in H. pylori intact cells (F–K) and cell lysates (L and M),
treated with or without CBS. Data are presented as the mean  SEM
from at least three independent experiments.
This journal is © The Royal Society of Chemistry 2017via the unique His- and Cys-rich C-termini.19,20 A time-
dependent increase in uorescence was observed upon mixing
HpHspA with Bi3+-TRACER, eventually leading to a ca. 5-fold
uorescence enhancement (Fig. 2B). Bi3+-TRACER was then
incubated with HpSlyD, HpHspA and their C-termini deleted
variants (HpSlyDDC and HpHspADC), and the samples were
subjected to UV irradiation at 365 nm for 10 min to allow the
formation of covalent bonds between the probe and proteins
prior to SDS-PAGE analysis; intense blue uorescence could
only be observed for the wide-type HpSlyD and HpHspA but not
for the C-termini deleted variants (Fig. 2C), conrming that Bi3+-
TRACER could label proteins with Bi-binding abilities on
a denatured gel. Upon photo-cross-linking, the dissociation of
Bi did not inuence the uorescent labelling. We then incu-
bated Bi3+-TRACER (50 mM) with H. pylori cells for 30 min and
intense blue uorescence was observed throughout the path-
ogen (Fig. 2D), suggesting that the probe could enter H. pylori
cells to label bismuth-binding proteins. Similarly, the labelledChem. Sci., 2017, 8, 4626–4633 | 4627
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View Article Onlineproteins were anchored to the probe by photo-activation of the
arylazide of the probe, and then separated by conventional two-
dimensional electrophoresis (2DE) (Fig. S2†), and subsequently
identied through peptide mass ngerprinting. A total of 46
bismuth-binding proteins in H. pylori were identied by using
Bi3+-TRACER (Table S1†).
We then used in-house continuous-ow gel electrophoresis
coupled with ICP-MS (GE-ICP-MS)20 to track intrinsic Bi3+-
binding proteins (Fig. 1B). H. pylori 26695 cells treated with CBS
(Colloidal Bismuth Subcitrate, 20 mgmL1 in culture) were lysed
and subsequently fractionated into soluble inner membrane
(sarkosyl soluble) and outer membrane fractions (SDS soluble)
using diﬀerent extraction buﬀers. The lysates were subjected to
GE-ICP-MS analysis. A total of 26 proteins, with 9 being
membrane proteins (Fig. S3†), were identied by GE-ICP-MS
(Table S1†), including pH-buﬀering enzymes, i.e. urease
subunits (UreA and UreB), and key ROS/RNS defence enzymes,
i.e. alkyl hydroperoxide reductase (TsaA), thioredoxin (TrxA) and
catalase (KatA). These proteins, which bind strongly to bismuth
even under denaturing conditions, might play crucial roles in
the susceptibility of H. pylori towards bismuth drugs.
To prole the intact proteome of H. pylori in response to
bismuth drugs, CBS-treated and untreated H. pylori 26695
protein extracts were compared in a quantitative iTRAQ exper-
iment (Fig. 1C). A 3-Plex iTRAQ isobaric labelling strategy21 was
applied to one control group and two CBS-treated groups.
Comparative analysis of the protein expression diﬀerences
between the control and two CBS-treated groups were quanti-
ed by LC-MS/MS. To improve the overall separation resolution
of liquid chromatography (LC) and to increase proteome
coverage, we applied an online three-dimensional (3D) RP-SCX-
RP LC system by combining two reverse-phase (RP) and one
strong cation exchange (SCX) mode.22 Using this system, 921
distinct proteins noted by at least two high-condence peptides
per protein with a condence level of 95% and global false
discovery rate (FDR) of less than 1% were identied from the H.
pylori iTRAQ samples, and 850 of them were identied from
technical duplicate runs, which achieved a high proteome
coverage of ca. 59% (921 of 1555 predicted proteins) in H. pylori
26695 identied by a single technique.23 In total 119 proteins,
including 34 up-regulated and 85 down-regulated proteins, were
identied as signicantly diﬀerentially expressed proteins (p <
0.05) with >1.30-fold or <0.77-fold change in abundance
compared to the control group (Table S3 and Fig. S4†).
We then selected 6 putative CBS protein targets including
GroEL, DnaK, AtpD, CagA, UreA and UreB, for verication using
cellular thermal shi assay (CETSA).24 Supplementation of 20 mg
mL1 CBS to the bacterial culture medium caused the thermal
melting curves of GroEL, DnaK, AtpD and CagA all to be shied
(Fig. 2F–I, Fig. S5†). However, to our surprise, we did not
observe obvious thermal shis of UreA and UreB in cells even
with the supplementation of up to 200 mg mL1 CBS (Fig. 2J and
K), which was likely due to the fact that the low concentrations
of bismuth uptaken by H. pylori25 is unlikely to saturate both
UreA and UreB given the high abundance of urease in the
pathogen. Indeed, the thermal stabilities of the two proteins
were shied upon the supplementation of 200 mg mL1 CBS to4628 | Chem. Sci., 2017, 8, 4626–4633H. pylori cell lysates (Fig. 2L and M). We also veried several
diﬀerentially expressed proteins identied upon bismuth
treatment, including UreA, AtpD, GroEL, ScoA and CagA, by
using western blotting. CBS treatment led to the expression
levels of UreA, CagA and ScoA to be decreased, whereas AtpD
and GroEL increased, which is consistent with iTRAQ-based
quantitative analysis (Fig. 2E).Disruption of multiple biological pathways by bismuth in H.
pylori
To functionally categorize the identied bismuth-associated
proteins, i.e. bismuth-binding and bismuth-regulated proteins,
we rst carried out the genome-wide Gene Ontology (GO) anno-
tation for H. pylori 26695 gene products as described in the
supplementary method. A total of 1340 diﬀerent Gene Ontology
(GO) terms assigned to 1067 distinct proteins in H. pylori 26695
were achieved, with an annotation coverage of 69% in the total
bacterium genes.
We then identied the functional PPI subnetworks that were
signicantly inuenced by the bismuth drug in H. pylori using
a home-made enrichment tool programmed in Python. A
number of PPI subnetworks, such as tricarboxylic acid cycle
(TCA, p ¼ 1.05  109), cell redox homeostasis (p ¼ 4.44 
109), nickel homeostasis (p ¼ 6.93  109), protein folding (p
¼ 1.95  108) and iron homeostasis (p ¼ 6.65  108), were
identied (Fig. S6A and Table S4†), providing clues for the
primary bismuth-targeting pathways in the bacterium.
We next examined the enrichment degrees of diﬀerent
enzymatic activities among the Bi-associated proteins (Table
S5†). We narrowed our analysis down to six enzymatic activities,
i.e. oxidoreductase activity, hydrolase activity, transferase
activity, ligase activity, lyase activity and isomerase activity, as
they were identied as the direct child GO terms of catalytic
activity (GO:0003824) among the 1055 annotated GO terms. The
enrichment analysis revealed that proteins possessing oxido-
reductase activity (p ¼ 5.74  107) were markedly inuenced
by CBS in H. pylori (Fig. S6B and C, Table S6†). Among these,
AhpC is a member of the ubiquitous 2-Cys peroxiredoxins
family, which h can prevent oxidative damage originating from
hydrogen peroxide, peroxynitrite and a wide range of organic
hydroperoxides through peroxidase activity, and is highly
expressed as the most abundant antioxidant protein in H.
pylori.26 Catalase is responsible for the removal of hydrogen
peroxide. Thioredoxin (TrxA), GroEL, neutrophil activating
protein (NapA) and the modulator of drug activity (MdaB) either
facilitate the regeneration of these antioxidant enzymes or
reduce indirectly the oxidative stress caused by CBS.
To experimentally validate the results obtained by bio-
informatics, we examined the eﬀect of CBS on the oxidative
stress defence systems in H. pylori. We found that bacterial
growth under various oxidative stress donors was almost
unperturbed in the absence of CBS (Fig. 3A), indicating that the
bacterium possesses its own defence systems to cope with
oxidative stress. In contrast, upon the supplementation of CBS
into the cell culture medium, the growth of H. pylori was
inhibited by nearly 70% under various oxidative stressesThis journal is © The Royal Society of Chemistry 2017
Fig. 3 CBS inhibits the growth of H. pylori by attacking the oxidative
stress defence and the pH-buﬀering systems. (A) Growth of H. pylori
under oxidative stress from various donors without (control) and with
CBS treatment. Under the stress of various ROS donors, the growth of
Bi-treated bacterium was signiﬁcantly lower than the control groups,
implying its reduced ability for defence against these oxidative stress
donors. The activities of three enzymes, AhpC, arginase and KatA, were
inhibited by Bi (B–D). (E) Intracellular pH of H. pylori indicated by the
ﬂuorescent probe LysoSensor™. Under acidic conditions (pH ¼ 4.0),
Bi-treated bacteria exhibited acidic intracellular pH, while the
untreated bacteria could keep the intracellular pH as neutral. Under
neutral conditions (pH ¼ 7.0), Bi treatment did not induce obvious
changes in the bacterial intracellular pH. The growth of Bi-treated
bacterium was signiﬁcantly inhibited under acidic conditions (F and G)
but not under neutral conditions (H and I). The diﬀerences in urease
activities (J–M) implied that Bi inhibited the enzyme function. (*, p <
0.05).
Fig. 4 CBS targets on the hub nodes of the protein–protein interac-
tion network in H. pylori and disrupts the functions of the hub protein
HpDnaK. (A) Bi-inﬂuenced protein–protein interaction (BiPI) network
in H. pylori. Proteins are coloured and shaped according to their
diﬀerent properties in the network. Nodes in the larger size represent
the central nodes with both high degree and BC values within the top
10% of the total nodes. (B) Average network degrees for hubs, non-
hubs and the identiﬁed Bi-binding proteins in the BiPI network are
compared. The identiﬁed Bi-binding proteins could be distinguished
from the non-hub proteins in the network. (C) Degree distribution of
the BiPI network in H. pylori. The number of nodes is plotted on the y-
axis, and the corresponding degrees are plotted on the x-axis. The
regression function and R2 coeﬃcients shown in the graph represent
the power law ﬁt yields. (D) ATPase activities ofHpDnaK in the absence
and presence of diﬀerent molar ratios of CBS (0.2-, 0.5- and 1.0-fold).
(E) Inﬂuence of CBS on the chaperone activity ofHpDnaK examined by
citrate synthase (CS) thermal aggregation assay. The light scattering of
CS was monitored at 360 nm. Data show one representative result of
three biological replications. (F) Glycolipid binding speciﬁcity of the N-
terminal domain of HpDnaK in the absence and presence of diﬀerent
molar ratios of CBS (1.0-, 5.0- and 10.0-fold). The asterisks indicate
that the results obtained with apo-DnaK are signiﬁcantly diﬀerent from
the Bi-bound DnaK, as compared by Student's t test (*, 0.01 < p < 0.05;
**, 0.001 < p < 0.01).
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View Article Online(Fig. 3A, Fig. S7†). We further examined the eﬀects of CBS on
several major antioxidant enzymes from H. pylori, i.e. AhpC,
KatA, SOD and arginase. Upon treatment of H. pylori with CBS,
the activities of AhpC, arginase and KatA were inhibited by 73%,
47% and 15%, respectively (Fig. 3B–D). Indeed, the binding of
bismuth to the conserved Cys169 of AhpC was conrmed by
IMAC, with the bismuth-binding motif 161HFEEHGEVC-
PAGW173 being identied.27 The signicant inhibition of AhpC
activities by CBS under the multiple turnover condition
(Fig. S8†) demonstrated the interference of bismuth on AhpC
regeneration. In contrast, no evident changes on the activity of
SOD were observed (Fig. S9†). We then determined the ROS
levels in H. pylori upon the treatment of CBS using a uorescent
probe HKSOX1.28 The green uorescent intensities increased
with the amounts of CBS (Fig. S10†), indicating the elevated
levels of intracellular oxidative stress caused by CBS.
To validate whether the bacterial pH-buﬀering function was
inuenced by CBS, we evaluated the intracellular pH of H. pylori
grown under acidic and neutral pH conditions with or without theThis journal is © The Royal Society of Chemistry 2017supplementation of CBS by a probe LysoSensor™, which gives
rise to yellow or green uorescence under acidic or neutral pH
conditions, respectively. As shown in Fig. 4E and Fig. S11 (ESI†),
under acidic conditions (pH ¼ 4.0), the bacterium appeared as
yellow upon CBS treatment, in contrast to green without CBS
treatment, indicating the bismuth drug abolished its pH-
buﬀering function under acidic conditions; whereas at neutral
pH condition (pH ¼ 7.0), CBS exhibited negligible inuences on
the intracellular pH of H. pylori (Fig. 3E). Consistently, upon
bismuth treatment, bacterial growth was inhibited by ca. 70%
under acidic conditions but was nearly unperturbed under
neutral conditions (Fig. 3F). To further interpret this phenom-
enon, we examined the urease activities at diﬀerent pHs with and
without CBS treatment correspondingly, as the survival and
colonization of the bacterium depend heavily on its ability to
produce an abundance of urease. About a 40% reduction in
urease activity was observed upon bismuth treatment under both
acidic and neutral conditions (Fig. 3J and L).Chem. Sci., 2017, 8, 4626–4633 | 4629
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View Article OnlineBismuth targets on the key nodes of the protein interaction
network in H. pylori
To understand the connections among the Bi-associated
proteins in H. pylori and to explore the network architecture
associated with the molecular mechanisms of action of bismuth
drugs, we mapped all the identied Bi-associated proteins onto
the protein–protein interaction networks in H. pylori. Starting
from a core set of 154 Bi-associated proteins, we extracted their
direct interacting proteins and constructed a Bi-inuenced
protein interaction (BiPI) network in H. pylori 26695, which
resulted in one giant BiPI network composed of 967 nodes,
connected via 2636 edges (Fig. 4A and Table S7†). Examination
of the shortest paths of the network showed that two randomly
selected nodes in the network were connected via 4.21 links,
suggesting that the nodes were very closely linked.
By measuring the slope of the regression line in the cumu-
lative distribution plot (Fig. 4C), the degree distribution of the
BiPI network was tted to a power law P(x)f x2.51, suggesting
the BiPI network followed a scale-free topology,29 i.e. a small
number of highly connected proteins participating in dozens of
processes and function as core proteins, while most of the other
proteins have only a few connections.29 The nodes with large
degree and high BC values were viewed as hub and bottleneck
nodes in a biological network (Table S8†). Five central nodes
with both high BC and large degrees within the top 1% of the
total nodes were highlighted in the BiPI network (Fig. 4A).
Notably, four out of the ve central nodes were identied as Bi-
binding proteins in H. pylori, including UreA and UreB, the
subunits of a key enzyme urease; RpoA, the subunit alpha of
DNA-directed RNA polymerase that catalyzes the transcription
of DNA into RNA using ribonucleoside triphosphates as
substrates; and DnaK, a major heat shock protein that could
express on the bacterial surface and is involved in the modu-
lation of glycolipid binding specicity of the bacterium.30 The
other hub protein NusG, which is down-regulated by bismuth,
participates in transcription elongation, termination and anti-
termination. By examining the average degrees and between-
ness values of the identied Bi-binding proteins in the BiPI
network, we found that the 63 Bi-targeting proteins could not
only be grouped with highly connected hub proteins, but also
could be characterized as bottleneck proteins in the network
(Fig. 4B and Table S9†). Given that targeting a highly connected
hub protein is more likely to be lethal to an organism than
targeting a non-hub protein,31 and it is also less likely to develop
drug resistance,32 the unique mode of action of a bismuth drug
may explain its lethality and lower likelihood to develop
resistance.
To the best of our knowledge, HpDnaK (Hsp70) was identi-
ed for the rst time to be a potential target of bismuth drugs.
We then experimentally validated this nding by overexpression
and purication of the protein to examine the interaction of Bi3+
with HpDnaK. The binding of Bi3+ to the cysteines of HpDnaK
was evidenced by the observation of a broad absorption band
centred at ca. 360 nm in the UV-vis diﬀerence spectra
(Fig. S12B†), with a stoichiometry of [Bi-NTA]/[HpDnaK] of
0.5 : 1, indicating that Bi3+ likely coordinates to the cysteines4630 | Chem. Sci., 2017, 8, 4626–4633from each HpDnaK monomer. A size exclusion chromatography
study showed that the binding of Bi3+ to HpDnaK induced
quaternary structural changes of the protein from a monomer
to a dimer (Fig. 4D).
To examine whether the bismuth drug functionally inhibited
HpDnaK, we rst determined the ATPase activity of HpDnaK in
the absence and presence of CBS. The rates of ATP hydrolysis
measured by monitoring the amounts of released free phos-
phate were found to be linear within 80 min (Fig. S12D†). A
marked decrease by 60% in the ATPase activity of HpDnaK was
observed in the presence of only 0.2 molar equivalent of CBS
(Fig. 4D); a further decrease in the activity but to a lesser extent
was seen with the addition of more CBS. We next examined the
inuence of CBS on the chaperone activity of HpDnaK using
citrate synthase (CS) as the substrate. As the heat-induced
aggregation of CS was obviously inuenced in the presence of
CBS (Fig. S12E†), only the eﬀects of the substoichiometric
concentrations of CBS were examined, and Bi-bound HpDnaK
was completely desalted before the assay to ensure the absence
of free bismuth. It was found that the presence of CBS disrupted
the protection eﬀect of HpDnaK on the aggregation of citrate
synthase to a certain extent (Fig. 4E), while the heat-induced
aggregation of apo- or Bi-bound HpDnaK was not observed
(data not shown). We further examined the glycolipid binding
property of the protein by modied ELISA. As the C terminus of
HpDnaK hydrophobically associates with the assay plates,
which readily interferes with the results, the N terminus of
HpDnaK (residues 1–377), which is the major functional
domain of DnaK for cell surface-associated glycolipid recogni-
tion,33 was expressed and puried for the assay. Dose-
dependent bindings of apo- and Bi-bound HpDnaK-N with
sulfatide were observed at low sulfatide concentrations (<200
ng), whereas the bindings of Bi-bound HpDnaK-N to sulfatide
remained almost unchanged at higher sulfatide concentrations,
indicative of a saturated binding. The sulfatide concentration
required to reach the saturation binding was decreased by ca. 4-
fold for Bi-bound HpDnaK-N in comparison to that for apo-
HpDnaK-N. In the presence of 10.0 molar equivalent of CBS,
additionally the binding of HpDnaK-N to sulfatide was reduced
by 32%, 37% and 44% at 200, 400 and 800 ng of sulfatide,
respectively (Fig. 4F). Taken together, Bi-binding decreased the
physiological ATPase activity, chaperone activity and glycolipid
(cerebroside sulfate) binding aﬃnity of DnaK, while glycolipid
binding is a common mechanism for bacterium-host cell
adhesion, indicating the potential of bismuth drugs in disrup-
tion of the interaction between H. pylori and its host gastric
epithelial cells.
Discussion
Proteome-wide proling of drug targets is a common strategy to
explore the mechanisms of action of many drugs and potential
carcinogens.34–36 Unlike organic drugs, metal ions or metal-
lodrugs oen exert their roles through binding and functional
perturbing of key proteins/enzymes; therefore, conventional
quantitative proteomics alone is not suﬃcient to uncover the
physiological and/or pathological biomolecular mechanisms ofThis journal is © The Royal Society of Chemistry 2017
Fig. 5 A model for the multi-targeted mode of action of CBS in
eradicating H. pylori. As experimentally validated in the current study,
bismuth drugs disrupt the oxidative stress defence and pH-buﬀering
abilities in H. pylori, and inhibit the normal functions of a newly iden-
tiﬁed potential key target HpDnaK, leading to various deleterious
eﬀects on the bacterium.
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View Article Onlinemetals. Similar to proteomics, metalloproteomics is emerging as
an important tool to reveal the roles of metals or metallodrugs in
disease processes and treatment.15–17 Owing to the complexity of
cellular metal-protein interactions, such as diﬀerent binding
aﬃnity (mM to pM) and dynamics (inert/labile), the proteome-
wide identication of metal-binding proteins is a signicant
challenge. Several metalloproteomic approaches have been
established;20,37,38 however, each has its pros and cons. Conven-
tional protein-based purication by liquid chromatography and
metal-based detection by high-throughput tandem mass spec-
trometry (HT-MS/MS) and inductively coupled plasma mass
spectrometry (ICP-MS) has oen led to losses of metals that bind
proteins weakly or transiently.38 Immobilized metal aﬃnity
chromatography (IMAC), albeit being frequently used to isolate
and enrich metal-binding proteins and motifs, suﬀers from
a number of drawbacks.39 In the present study, by integrating
our in-house metalloproteomics with quantitative proteomics,
we were able to uncover the maximum numbers of proteomes
responsive to the drug treatment, including 63 Bi-binding and
119 Bi-regulated proteins, nearly 10-fold more than previously
identied,20,40 thus providing a rich resource of potential drug
targets in H. pylori.
To functionally categorize the identied bismuth-associated
proteins, we rst performed the genome-wide GO annotation to
the H. pylori 26695 gene products by using an in-house
enrichment tool. Notably, based on the newly constructed H.
pylori GO database, we found that over 60% of the identied Bi-
associated proteins were annotated with catalytic functions,
which is in accordance with the hypothesis that antimicrobial
metal species mainly abolish the activities of various enzymes to
exert their toxicities in bacteria.5 Bioinformatics analysis
showed that bismuth disrupts multiple biological pathways
critical for the pathogen. Among the major enzymatic activities
in H. pylori, oxidoreductase and hydrolase are the two major
enzymatic activities that are signicantly inuenced by the
bismuth drug. Defence against oxidative stress is crucial for H.
pylori survival as the bacterial infection could induce inam-
matory response, resulting in an oxidative burst, which would
accumulate in the stomach and rapidly eliminate the bacterium
in the absence of appropriate defences.41 Similarly, the survival
and colonization of the bacterium depend heavily on its ability
to produce an abundance of urease, a cytosolic metalloenzyme
that catalyzes the hydrolysis of urea to ammonia, which eﬀec-
tively buﬀers its intracellular pH and creates a neutral layer
around the bacterium,42,43 which is important given the special
niches in which H. pylori resides. Subsequent experimental
validation showed that bismuth drugs impair the oxidative
defence systems and abolish the bacterial pH-buﬀering ability,
possibly by binding and functionally disrupting key enzymes.
Furthermore, based on the Bi-inuenced protein interaction
network in H. pylori, we found that the identied Bi-binding
proteins had a high tendency to be grouped with hub proteins
in the network. Given that highly connected hub nodes are
generally essential for the integrity and stability of a PPI
network, disruption of the function of a highly connected hub
protein is more likely to be lethal to the organism than targeting
a non-hub protein.44–46 Moreover, targeting hub proteins byThis journal is © The Royal Society of Chemistry 2017a drug is also featured as less likely to develop drug resistance,
as proteins with more interactors are more tolerant to muta-
tions.47 Five central nodes were uncovered in the BiPI network,
with four of them being Bi-binding proteins in H. pylori. Apart
from UreA and UreB, subunits of urease, which is well recog-
nized to be one of the targets of bismuth drugs,20,40 DnaK, RpoA
and NusG were also situated in the central nodes, and appeared
to be newly identied targets of bismuth drugs. We selected
DnaK for further validation by purication of the protein and in
vitro examination of the binding and functional inhibition by
CBS. A biophysical study and enzymatic assay showed that Bi3+
indeed bound to DnaK and decreased the physiological ATPase
activity and glycolipid (cerebroside sulfate) binding aﬃnity of
DnaK. While the latter is a common mechanism for bacterium-
host cell adhesion,48,49 this provides the rst molecular insight
into bismuth inhibition of the interaction between H. pylori and
its host gastric epithelial cells.50
Conclusions
In summary, the integration of metalloproteomics with quanti-
tative proteomics, in combination with bioinformatics analysis
and bioassays, enabled the systemic characterization of the
cellular response triggered by metal-based therapies. Our studies
demonstrate that the multi-targeted mode of action of a bismuth
drug (Fig. 5, Fig. S13†) is accountable for its sustainable anti-
microbial activity against H. pylori and the low likelihood of H.
pylori developing resistance to bismuth drugs. This study may
shed light on the design of new types of antibiotics or the reuse of
metals to enhance the therapeutic eﬀects of conventional anti-
biotics to relieve the current crisis of antimicrobial resistance.
The integrative approach we report herein provides a general
platform for understanding the physiological and pathological
roles of metals as well as the mechanism of metallodrugs.
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